IP Library Granted Patent US 11,179,553
Granted Patent B2
US 11,179,553 · App. 14/351,499 · Granted Nov 23, 2021

Delivery device

Inventors: Mark Anthony Fernance Kendall (Chelmer, AU); Stefano Meliga (West End, AU); Alexandra Christina Isabelle Depelsenaire (Yeerongpilly, AU); Michael Lawrence Crichton (Auchenflower, AU); Christopher Flaim (Kenmore, AU)
Assignee: VAXXAS PTY LIMITED
A61M37/0015A61B17/205A61K9/0021A61M37/00A61M2037/0023A61M2037/0046
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,179,553
App. No.
14/351,499
Granted
Nov 23, 2021
Kind
B2
Abstract

A device for delivery of material to a biological subject, the device including a base and a number of projections extending from the base, each projection including a tip for penetrating tissue of the biological subject, at least a portion of at least one of the projections being coated with a non-liquid coating including the material. At least the tip of at least one of the coated projections may have a convex effective profile. The device may be for delivery of material to a dermal layer of the biological subject. In another aspect an applicator for applying the device to the biological subject applies a preload force to the tissue such that the force at least partially compresses a subcutaneous tissue layer of the biological subject prior to application of the device, and applies the device with a predetermined velocity, wherein tissue stiffness is maintained and/or the projections penetrate the tissue to a predetermined depth.

Claims (18)

1. A device for delivery of a biochemical compound to a biological subject, the device comprising:

a) a base; and,

b) a number of solid, non-porous projections extending from the base, wherein each projection comprises a cylindrical support section which transitions into a coated, convex end section having a tip, wherein the transition forms a flat stepped surface profile between the end section and the cylindrical support section and wherein the cylindrical support section is wider at the transition than the coated end section and a discontinuity wherein the discontinuity is closer to the base than the flat stepped surface profile such that the flat stepped surface profile and the discontinuity of each projection interact with tissue of the biological subject to at least partially control penetration of the projections into the tissue thereby providing a physical adjuvant effect, when the device is applied to the tissue so that the projections penetrate the tissue,

wherein a cone angle measured from a centerline of each projection to an edge of the coated, convex end section having a tip varies along a length of at least one of the projections and wherein the cone angle increases along the length of the end section and wherein the cone angle is between 1° and 10° at the tip.

2. The device according to claim 1 , wherein the flat stepped surface profile is located at a distance from the tip of the end section, the distance being between 10 and 100 μm.

3. The device according to claim 1 , wherein at least one of the projections has a length between 200 μm and 250 μm.

4. The device according to claim 1 ,

wherein:

i) the number of projections is from about 1000 to 20000;

ii) at least one of the projections has a length of between 200 μm and 250 μm;

iii) at least one of the projections has a base width of between 20 μm and 50 μm;

iv) at least one of the projections has a tip radius of less than 5 μm; and

v) the projections are separated by a spacing of between 70 μm and 100 μm.

5. The device of claim 1 , wherein the coated, convex end section is coated with a first vaccine compound and wherein at least one of the projections is coated with a second vaccine compound.

6. The device of claim 1 , wherein the biochemical compound is sprayed onto the projections.

7. The device of claim 1 , wherein the base is 1 mm 2 to 100 mm 2 .

8. The device of claim 1 wherein the physical adjuvant effect is cell damage mediated by the projections.

9. The device according to claim 1 , wherein the flat stepped surface profile step is located at a distance from the tip of the end section, the distance being between 40 and 60 μm.

Assignments (4)
CHANGE OF ADDRESS Recorded Feb 20, 2018
From: VAXXAS PTY LIMITED
To: VAXXAS PTY LIMITED
Reel/Frame 045640/0798 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 23, 2017
From: THE UNIVERSITY OF QUEENSLAND
To: UNIQUEST PTY LIMITED
Reel/Frame 043368/0707 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 23, 2017
From: UNIQUEST PTY LIMITED
To: VAXXAS PTY LIMITED
Reel/Frame 043456/0271 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 7, 2014
From: KENDALL, MARK ANTHONY FERNANCE; MELIGA, STEFANO; DEPELSENAIRE, ALEXANDRA CHRISTINA ISABELLE; CRICHTON, MICHAEL LAWRENCE; FLAIM, CHRISTOPHER
To: THE UNIVERSITY OF QUEENSLAND
Reel/Frame 033253/0407 →
Priority Claims (1)
AU 2011904174 · Oct 12, 2011 · national
Continuity (1)
Related Publication 20140257188A1 · Sep 11, 2014
Cited By (7)
US 12,186,515 US 12,403,292 US 12,491,351 US 12,708,750 US 12,714,838 US 12,734,346 US 12,734,730